Core Viewpoint - The company, Jiangsu Wuzhong Pharmaceutical Development Co., Ltd., is facing significant risks due to an investigation by the China Securities Regulatory Commission (CSRC) and the freezing of several bank accounts due to overdue loans, which may impact its financing capabilities and operations [2][4]. Group 1: Bank Account Freezing - The company and its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Sales Co., Ltd., have had a total of 31 bank accounts frozen, with a total amount of approximately RMB 2.65 million, accounting for 0.15% of the company's latest audited net assets [2][3]. - The freezing of accounts is primarily due to a financial loan dispute with Nanyang Commercial Bank (China) Co., Ltd., Suzhou Branch, where the subsidiary has an overdue loan of RMB 20.96 million [3][4]. Group 2: Impact on Operations - Currently, the company's production and operations are proceeding normally, and the freezing of bank accounts has not significantly affected its cash flow or operational activities [4]. - However, the ongoing investigation by the CSRC and the overdue debts may lead to a decline in the company's financing capabilities, potentially impacting some business operations [4]. Group 3: Response Measures - The company is actively communicating with relevant parties to resolve the issues related to the frozen accounts and is seeking new financing channels and optimizing its debt structure to mitigate debt risks [5].